An Open-Label Extension of Study Fx-005 Evaluating Long-Term Safety and Clinical Outcomes of Fx-1006A in Patients with Transthyretin Amyloid Polyneuropathy - Not applicable

FoldRx Pharmaceuticals, Inc.0 个研究点目标入组 107 人开始时间: 2008年4月21日最近更新: 2012年7月24日

适应症

试验速览

暂无简介。

•Inclusion Criteria for male and non-pregnant female patients:
•- Patient has completed the Month 18 visit of Study Fx-005.
•- If female, patient is post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide) throughout the study. (A condom alone is not considered an acceptable method of birth control.) If male with a female partner of childbearing potential, willing to use an acceptable method of birth control for the duration of the study. For both females and males, acceptable birth control must be used for at least 3 months after the last dose of study medication.
•- Patient is, in the opinion of the investigator, willing and able to comply with the study medication regimen and all other study requirements.
•- Patient agrees not to participate in another investigational drug or device study while participating in this open-label extension study.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Patients meeting any of the exclusion criteria will not be enrolled in the study:
•- Chronic use of non-protocol approved non-steroidal anti-inflammatory drugs (NSAIDs), defined as greater than 3-4 times/month. The following NSAID are allowed: acetylsalicylic acid, etodolac, ibuprofen, indomethicin, ketoprofen, nabumetone, naproxen, nimesulide, piroxicam, and sulindac.
•- If female, patient is pregnant or breast feeding.
•- Patient has liver function test abnormalities: alanine transaminases (ALT) and/or aspartate transaminases (AST) >2 times upper limit of normal (ULN) that in the medical judgment of the investigator are due to reduced liver function or active liver disease

发起方